SDH is a protein that is based in the mitochondria. Its loss causes a major energy and metabolic crisis. Despite this, some types of cells can ‘benefit’ from the loss of SDH and continue to grow uncontrollably and generate tumors.

Identifying metabolic enzymes as molecular drug targets that are uniquely essential for the survival of SDH-deficient cells is a key first step in the development of new therapies for SDH-deficient tumors. Some of these druggable enzymatic targets are being actively pursued.

Dr. Eyal Gottlieb broke down the biology of cells and discussed metabolism and growth during cancer formation.
This webcast was geared for patients and families with SDH-deficient GIST and other tumors.


Dr. Eyal Gottlieb

Dr. Eyal Gottlieb
Laura and Isaac Perlmutter Chair of Cancer Research,
Faculty of Medicine
Technion – Israel Institute of Technology
Haifa, Israel

Originally presented on Wednesday September 5, 2018 at 12:00-1:00 PM (Eastern Time/NY)
For background information on cancer metabolism, review this document.
Answers to submitted questions can be reviewed here.